MABION SA ZY -,10

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, MABION SA ZY -,10 had revenue of €759.03k and net profit of -€3.47m

(EUR)	June 2026	YoY
Revenue	759.03k	1.20%
Gross profit	-794.62k	36.12%
Net profit	-3.47m	4.34%
EBITDA	-814.16k	71.79%

Fundamentals

Metric	Value
Market capitalization	€29.28m
Number of shares	16.16m
52-week high/low	€2.27 - €1.52
Dividends	No
Beta	0.38
P/E ratio	-2.28
PEG ratio	-0.18
P/B ratio	5.33
P/S ratio	7.31

Company profile

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.